FDA Seeks Injunction Against ‘Anticancer’ Drug Maker

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 9 No 3
Volume 9
Issue 3

ROCKVILLE, Md-The FDA has accused Lane Labs-USA, Inc., of Allendale, NJ, with illegally promoting three products as treatments for cancer and other diseases, and is seeking a permanent federal court injunction against the marketing of the products: BeneFin, produced from shark cartilage; SkinAnswer, a glycoalkaloid skin cream; and MGN-3, a rice-bran extract.

ROCKVILLE, Md—The FDA has accused Lane Labs-USA, Inc., of Allendale, NJ, with illegally promoting three products as treatments for cancer and other diseases, and is seeking a permanent federal court injunction against the marketing of the products: BeneFin, produced from shark cartilage; SkinAnswer, a glycoalkaloid skin cream; and MGN-3, a rice-bran extract.

The FDA noted that BeneFin is being studied as a cancer therapy under an investigational new drug application and it can be distributed for clinical trials. The legal action does not affect shark cartilage products that are lawfully marketed as dietary supplements.

Recent Videos
Brett L. Ecker, MD, focused on the use of de-escalation therapy, which is gaining momentum in neuroendocrine tumors.
Immunotherapy options like CAR T-cell therapy and antigen-presenting cell-directed agents are currently being evaluated in the pancreatic cancer field.
Certain bridging therapies and abundant steroid use may complicate the T-cell collection process during CAR T therapy.
Pancreatic cancer is projected to become the second-leading cause of cancer-related deaths by 2030 in the United States.
2 experts are featured in this video
2 experts are featured in this video
2 experts are featured in this video
4 KOLs are featured in this series.
Related Content